Skip to main content

Table 1 Baseline characteristics by treatment group

From: Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

Parameter ERN/LRPT    Placebo   
(N = 393) (N = 323)
Overall Population Baseline TG subgroup Overall Population Baseline TG subgroup
   <2.26 mmol/L (n = 320) ≥2.26 mmol/L (n = 73)   <2.26 mmol/L (n = 279) ≥2.26 mmol/L (n = 44)
Age, mean ± SD, y 61.80 ± 9.29 62.08 ± 9.27 60.58 ± 9.36 61.77 ± 9.43 62.04 ± 9.33 60.09 ± 9.99
Age, median (range), y 63 (31–79) 63 (33–79) 61 (31–76) 63 (21–80) 63 (21–80) 63 (36–77)
Sex, no. (%)       
 Male 233 (59.3) 187 (58.4) 46 (63.0) 208 (64.4) 182 (65.2) 26 (59.1)
 Female 160 (40.7) 133 (41.6) 27 (37.0) 115 (35.6) 97 (34.8) 18 (40.9)
Population subgroups, no. (%)a       
 Statin-treated 310 (78.9) 259 (80.9) 51 (69.9) 259 (80.2) 227 (81.4) 32 (72.7)
 Other LMT-treated 33 (8.4) 24 (7.5) 9 (12.3) 34 (10.5) 28 (10.0) 6 (13.6)
 Drug naive 72 (18.3) 54 (16.9) 18 (24.7) 55 (17.0) 47 (16.8) 8 (18.2)
BMI, mean ± SD, kg/m2 31.28 ± 6.45 30.90 ± 6.43 32.93 ± 6.34 30.48 ± 5.83 30.26 ± 5.92 31.84 ± 5.01
Baseline values, mean ± SD       
 apoB, g/L 0.93 ± 0.19 0.90 ± 0.17 1.1 ± 0.18 0.91 ± 0.17 0.89 ± 0.15 1.1 ± 0.20
 TC, mmol/L 4.30 ± 0.68 4.20 ± 0.67 4.69 ± 0.58 4.21 ± 0.64 4.14 ± 0.60 4.65 ± 0.75
 Non-HDL-C, mmol/L 3.00 ± 0.64 2.85 ± 0.57 3.64 ± 0.54 2.91 ± 0.58 2.81 ± 0.50 3.53 ± 0.64
 HDL-C, mmol/L 1.29 ± 0.36 1.35 ± 0.35 1.04 ± 0.25 1.30 ± 0.34 1.33 ± 0.35 1.12 ± 0.25
 LDL-C, mmol/L 2.26 ± 0.53 2.26 ± 0.53 2.27 ± 0.55 2.20 ± 0.47 2.19 ± 0.44 2.27 ± 0.61
 TGb, mmol/L 1.42 (0.36–7.10) 1.27 (0.36–2.23) 2.88 (2.28–7.10) 1.45 (0.44–5.75) 1.32 (0.44–2.24) 2.63(2.26–5.75)
 CRPb, mg/L 1.8 (0.1–56.2) 1.7 (0.1–56.2) 2.3 (0.3–36.3) 1.5 (0.1–69.7) 1.5 (0.1–69.7) 1.40 (0.3–15.7)
 FPG, mmol/L 7.29 ± 1.81 7.10 ± 1.63 8.11 ± 2.28 7.41 ± 1.79 7.38 ± 1.83 7.62 ± 1.59
 HbA1c, % 6.91 ± 0.72 6.86 ± 0.69 7.11 ± 0.81 6.90 ± 0.70 6.89 ± 0.69 6.97 ± 0.74
  1. ApoB apolipoprotein B; BMI body mass index; ERN/LRPT ER niacin/laropiprant; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; TC total cholesterol; TG triglyceride; CRP C-reactive protein; FPG fasting plasma glucose; HbA1c hemoglobin A1c
  2. aBecause a patient can be taking both a statin and another LMT at baseline, the total percentage may be greater than 100 %
  3. bExpressed as median